Posted by Michael Wonder on 10 Nov 2022
MSAC can't find a place for Carvykti
10 November 2022 - The outcome from Janssen's application requesting the public funding of ciltacabtagene autoleucel for the treatment of adults with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an antiCD38 antibody has finally been published.
The MSAC considered there was high uncertainty regarding the clinical place of ciltacabtagene autoleucel and the proposal for its use as a later line of therapy in the context of relapsed refractory multiple myeloma, which has a long disease history with many alternative and new treatment options that have improved patient outcomes.
